期刊
ANNALS OF INTERNAL MEDICINE
卷 150, 期 12, 页码 858-U63出版社
AMER COLL PHYSICIANS
DOI: 10.7326/0003-4819-150-12-200906160-00009
关键词
-
资金
- Heart and Stroke Foundation of Ontario [CI-5710, PRG-5967, NA-Review 6059, T-6018]
- Canadian Institutes for Health Research [MOP-13430, MOP-39533, MOP-39833]
- Ontario Research Fund
- Ontario Genomics Institute
Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid-binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据